Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris

Sarrafzadegan, Nizal; Sadeghi, Masoumeh; Ghaffarpasand, Fariborz; Alisaeidi, A.; Sanei, Hamid; Zakeri, Habib; Rastegar, T.; Amiri, Ali; Dehghankhalili, Maryam

doi:10.1007/s00059-012-3648-3

Cited by 4 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…20 This finding was consistent with those of Sarrafzadegan et al, Tang et al and Caselli et al who too had reported higher concentrations of IL-6 in patients with stable angina. [21][22][23] In addition, IL-6 levels also reflect the degree of vascular inflammation and the severity of CAD. Mokhtar et al found significant increase in serum level of IL-6 in MVD and SVD patients as compared with non-CAD patients, a finding seen in our patients too.…”

Section: Discussionmentioning

confidence: 99%

High-sensitivity C-reactive protein and interleukin-6 as risk predictors in patients with stable angina pectoris

et al. 2020

View full text Add to dashboard Cite

Background: Cardiovascular diseases are a leading cause of morbidity and mortality especially in developing countries such as India. Biomarkers such as high-sensitivity C-reactive protein (Hs-CRP) and interleukin-6 (IL-6) can help in risk stratification and better management of patients with stable angina.Methods: This was a prospective observational study wherein symptomatic patients with stable angina were enrolled. Coronary angiogram was done in those consenting to the procedure. Severity of coronary stenosis was graded as per the modified Gensini score (mGS). Hs-CRP and IL-6 levels were determined pre-procedure and 24 hours post percutaneous coronary intervention (PCI). Based on angiographic profile, patients were subdivided into four groups: group 1: normal coronaries, group 2: single vessel disease, group 3: double vessel disease and group 4: triple vessel disease. Primary outcome was occurrence of major adverse cardiovascular events over one-year period.Results: A total of 158 patients completed the study with a mean age of 62.8±9.6 years. A significant difference was observed between the four groups in terms of age, Hs-CRP and IL-6 levels. Of the 124 patients undergoing PCI, significant difference was observed in terms of pre and post procedure Hs-CRP (P<0.0001) and IL-6 levels (P<0.0001). Strong positive correlation was seen between Hs-CRP and IL-6 levels with modified Gensini scoring (mGS). Patients with MACE (15/158; 9.4%) had significantly higher levels of Hs-CRP and IL-6. Multivariate logistic regression analysis revealed that Hs-CRP, IL-6, ΔHs-CRP and ΔIL-6 were independent predictors of major adverse cardiovascular events (MACE).Conclusions: Hs-CRP and IL-6 levels were independent predictors of outcomes and can be used for risk stratification in these patients..

show abstract

Section: Discussionmentioning

confidence: 99%

High-sensitivity C-reactive protein and interleukin-6 as risk predictors in patients with stable angina pectoris

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, the relationship between IL-6 and ACS is not consistent across other studies. One study showed that IL-6 levels in patients with unstable angina were significantly higher than those in patients with ACS (102.4 ± 1.9 vs 224.6 ± 3.6, P = 0.007) (Sarrafzadegan et al, 2012). Therefore, the relationship between IL-6 and ACS needs further clarification.…”

Section: Introductionmentioning

confidence: 99%

Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome

Wang¹,

Liu²,

Wang³

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Serum high-sensitivity C-reactive protein (hs-CRP) is a sensitive indicator of inflammation, which is closely related with the progress of plaque formation. Interleukin-6 (IL-6) is one of the inflammatory markers of local coronary plaque and the peripheral blood cycle, promoting the occurrence of atherosclerosis development and plaque rupture. In this study, the correlation of hs-CRP and IL-6 was investigated in patients with acute coronary syndrome (ACS). Sixty cases of ACS, including 33 cases of acute myocardial infarction (AMI) and 27 cases of unstable angina pectoris (UAP), 45 cases of stable angina pectoris (SAP), and 45 healthy people (HG) were enrolled in study. The serum hs-CRP and serum IL-6 levels were tested by the immune turbidimetric method and enzyme-linked immunosorbent assay (ELISA), respectively. The differences among groups and their correlations were evaluated. Results showed that the serum hs-CRP and IL-6 concentrations of the AMI and UAP groups were significantly higher than those of the SAP and HG groups, respectively (P < 0.01), and those of the AMI group were significantly higher than those of the UAP group (P < 0.05). The serum hs-CRP and IL-6 levels of the ACS Correlation of C-reactive protein and interleukin-6 group were positively correlated (r = 0.836). The serum hs-CRP and IL-6 levels could be used to determine the stability of plaque, and have some relevance in the ACS process, showing great value in judgments of ACS prognosis.

show abstract

Uterine Fibroids: Response to novel treatment modalities

Quinn¹

2013

View full text Add to dashboard Cite

Interleukin-6 and E-selectin in acute coronary syndromes and stable angina pectoris

Abstract: In the current study, inflammation as measured by IL-6 and E-selectin was not found to play an important role in progression of ischemic heart disease from stable angina to unstable angina or myocardial infarction, which is contrary to previous studies.

Cited by 4 publications

References 31 publications

High-sensitivity C-reactive protein and interleukin-6 as risk predictors in patients with stable angina pectoris

High-sensitivity C-reactive protein and interleukin-6 as risk predictors in patients with stable angina pectoris

Correlation of serum high-sensitivity C-reactive protein and interleukin-6 in patients with acute coronary syndrome

Uterine Fibroids: Response to novel treatment modalities

Contact Info

Product

Resources

About